CTLA4 and neoplasm: Among all five patients with clinical benefit, T-cell exhaustion (CD8+ PD-1/CTLA-4+) and treatment-induced depletion of Tregs (CD4+ FOXP3/CTLA-4+) were identified in either tumor or blood; However, only one non-responder showed similar immune markers, indicating that appropriate patient selection with the exhausted CD8+ T cell immune signature is feasible [29].